Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.52 |
| ▸ | DRD3 | P35462 | 9/20 | 0.52 |
| ▸ | DRD2 | P14416 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313185 | 1.00 | KCNH2 (0.52) | KCNH2DRD3DRD2 | |
| SCHEMBL3769913 | 1.00 | KCNH2 (0.52) | KCNH2DRD3DRD2 | |
| SCHEMBL3769912 | 1.00 | KCNH2 (0.52) | KCNH2DRD3DRD2 | |
| SCHEMBL11915231 | 1.00 | KCNH2 (0.52) | KCNH2DRD3DRD2 | |
| SCHEMBL11911756 | 1.00 | KCNH2 (0.52) | KCNH2DRD3DRD2 | |
| SCHEMBL4629032 | 0.86 | KCNH2 (0.49) | KCNH2DRD3DRD2 | |
| SCHEMBL13823162 | 0.86 | KCNH2 (0.49) | KCNH2DRD3DRD2 | |
| SCHEMBL8247741 | 0.86 | KCNH2 (0.49) | KCNH2DRD3DRD2 | |
| SCHEMBL13201887 | 0.86 | KCNH2 (0.49) | KCNH2DRD3DRD2 | |
| SCHEMBL10235477 | 0.86 | DRD3 (0.42) | KCNH2DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891056-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227837-A1 | Novel Compounds | HTR5A, NPY5R, DRD3 | KCNH2 194/4885DRD3 3/4885DRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.